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Abstract 
Background and Aims: Hepatitis C virus (HCV) is a member of the Flaviviridae family, 
which causes approximately 500,000 deaths annually. HCV infection treatment is often 
associated with significant adverse effects. Curcumin is an active ingredient of turmeric 
which has therapeutic anti-inflammatory effects in many diseases including infectious ones. 
Although curcumin is not soluble in water, if it is synthesized in the form of nanomicelles, it 
will be water soluble and can be absorbed in the gastrointestinal tract (GI). In this study, the 
antiviral effects of curcumin nanomicelles were investigated on the attachment and entry of 
HCV particles. 
Materials and Methods: The cytotoxicity of curcumin nanomicelles was determined in 
Huh7.5 cells and their antiviral effects on the attachment and entry of HCV was investigated 
in a cell culture system. 
Results: Curcumin nanomicelles could decrease the viral load in the cell culture supernatants 
compared to virus control. 
Conclusions: According to the results of this research, we determined the antiviral effects of 
curcumin nanomicelles in the later stages of HCV replication. 
Keywords: Hepatitis C virus, Curcumin, Herbal medicines, Nanomicelles. 
 
 
Introduction
*
 
 
epatitis C is an infectious disease of 
the liver, which is caused by hepatitis 
C virus (HCV). HCV is a member of 
the family Flaviviridae (1), consisting of 
several genotypes. Genotypes 1 and 4 of this 
virus were found to be more resistant to 
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treatment than genotypes 2 and 3. The most 
important drugs that are used to treat HCV 
infection are Ribavirin and peginterferon. But, 
only about 40 to 50% of patients with genotype 
1 infection can get cured. The new approved 
drugs for treatment of this infection are 
Telaprevir, Paritaprevir, Boceprevir, and 
Simeprevir, which inhibit NS3/4A protease. 
Daclatasvir inhibits NS5A and Sofosbuvir 
inhibits NS5B (2-4). As herbal medicines are 
safe, effective, and inexpensive; they have 
attracted many attentions (5). Previous 
investigations have shown that there are some 
herbal medicines, which have anti HCV effects 
including Milk Thistle, Glycyrrhizin, Kampo, 
Phyllanthus, Cinnamon, and Curcumin (6-14). 
H 
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Curcumin is a yellow substance derived from 
the rhizome of Turmeric which has a lot of 
benefits such as being antioxidant and anti-
inflammation. Curcumin is able to bind some 
metals such as iron and copper (15). According 
to series of studies, curcumin has an anti-
microbial effect on different kinds of bactria 
and viruses including HIV, Influenza virus, 
Herpes simplex virus-1 and 2, Coxsackievirus, 
Hepatitis B virus, HCV, Human 
Papillomavirus, and Japanese encephalitis 
virus (16-24).  
Nanomicelles are self-assembled nano-sized 
(10 to 100 nm) particles that can be used as 
drug carriers for various therapies. Their 
structure consists of a hydrophilic core and a 
hydrophobic shell (25). One study showed that 
curcumin nanomicelles have anti-HTLV-1 
effect (26). 
The goal of this study was to evaluate the 
antiviral effects of curcumin nanomicelles on 
the attachment and entry of HCV infection in 
cell culture. 
 
Methods 
 
Cell culture and virus reproduction. In this 
study, JFH1 vector harboring HCV genotype 
2b isolate and its appropriate cell line for 
propagation (Huh7.5) were used to produce 
HCV particles. JFH1 vector and Huh7.5 cells 
were provided under an MTA agreement 
[ACADEMIC MATERIAL TRANSFER 
AGREEMENT (MTA 1832, APP1025 pJFH1, 
APC49 Huh7.5 cells)] between Apath, L.L.C., 
a limited liability corporation of the State of 
Missouri and Mashhad University of Medical 
Sciences (MUMS). As previously described 
(27), Huh7.5 cells were cultured in DMEM/ 
high glucose (Biosera, France) supplemented 
with 10% of FBS (Gibco, the USA) and 1% of 
Penicillin and Streptomycin antibiotics 
(caisson, the USA). When the confluency of 
the cells reached about 70 %, the residual 
media were removed and cells were inoculated 
by viruses. After 48-72 hr of incubation, the 
supernatants containing viruses was collected.   
MTT Assay. MTT Assay was used to 
determine cytotoxicity of curcumin 
nanomicelles and peginterferon asa control 
drug. Briefly, Huh7.5 cells were cultured in a 
96 well plate; each well contained about 10000 
cells. The plate was incubated at 37ºC with 5% 
CO2 for 24 hr.  Eight 2-fold serial dilutions of 
peginterferon were made from 180 mg/mL 
stock solution( 1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 
1:64, 1:128). For curcumin nanomicelles, three 
concentration of 0.256, 0.128, and 0.032 
mg/mL were made. After removing media, 
different concentrations of peginterferon and 
curcumin nanomicelles were added to wells. 
Each concentration of either treatment was 
tested in triplicate. Then, the plate was 
incubated for 24 hr. The media of the wells 
was removed. Subsequently, 100 microliter of 
new media plus 10 µl of MTT reagent was 
added to each well. After 4 hr of incubation at 
37ºC under 5% of CO2, 100 microliters of 
DMSO was added to each well. Eventually, the 
optical density was read at 570 and 630 nm by 
an ELISA reader. 
 
IC50 Determination. The concentration 
induced 50% cytotoxicity (IC50) was 
calculated using Microsoft Office Excel and 
CalcuSyn software (Biosoft, version 2/1). 
Exposing the virus to peginterferon and 
curcumin nanomicelles 
Approximately, 10000 cells were seeded in 
each well and the plate was put in an incubator 
at 37ºC under 5% of CO2 for 24 hr. Fifty µl of 
the virus and 200 µl of 1 IC50 of either 
peginterferon or curcumin nanomicelles were 
mixed and kept at 4ºC. After discarding the 
media, the mixtures of the virus with 
peginterferon and/or curcumin nanomicelles 
were added to the wells. Eventually, the 
supernatant of each well was collected after 48 
hr and was used save for RNA extraction. 
 
RNA extraction and Real Time PCR. RNA 
extraction was performed using Genet Bio kit 
(South Korea). Then, Real Time PCR was 
done by Iranian Noving Gene kit (Iran) using 
Corbett Rotor Gene. 
 
Results 
 
Cell culture. Figure 1 shows Huh7.5 cells 
attached to the flask bottom as monolayer 
epithelial cells. 
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MTT assay and IC50 determination. The 
percentage of the viable cells against different 
concentration of peginterferon and curcumin 
nanomicelles was determined using MTT 
assay.  
Chart 1 shows the viability of Huh7.5 cells 
following exposure to different concentrations 
of peginterferon. The highest concentration 
was 0.18 mg/mL.  
 
 
Chart 2 shows the viability of Huh7.5 cells 
against different concentrations of curcumin 
 nanomicelles. The highest concentration was 
0.256 mg/mL. 
 
 
 
The IC50 values of peginterferon and 
curcumin nanomicelles were obtained from the 
dose response curves (Figures 2 and 3).  
 
. 
 
Chart.  1.  Cytotoxicity effect of peginterferon on 
Huh7.5 cell line. 
 
 
Fig.  2.  The dose–effect curve of peginterferon. 
 
 
Fig.  1.  Hhu7.5 cells. The image was taken by an 
inverted microscope with 100 X magnification. 
 
Fig.  3.  The dose–effect curve of curcumin 
nanomicelles. 
 
 
Chart.  2.  Cytotoxicity effect of curcumin 
nanomicelles on Huh7.5 cell line. 
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The values of IC50 for Huh7.5 cells were 
achieved as 0.03298 mg/mL and 0.1647 
mg/mL in the cases of peginterferon and 
courcumin nanomicelles, respectively. 
 
Chart 3 shows the Sigmoid curves of virus 
multiplication and chart 4 illustrates the 
standard curve based on the concentrations 
against CT values. According to Real Time 
PCR results (R=0.996, Efficiency= 1.05), the 
viral load of virus control and virus in 
combination with peginterferon, and curcumin 
nanomicelles were 1250, 4000 and 1000 
IU/mL, respectively. 
 
Discussion 
 
HCV is one of the infectious agents that causes 
liver cirrhosis and liver cancer (28). More than 
185 million people (2.8 % of the world 
population) were estimated to be infected by 
this virus. About 500000 people died due to 
this infection annually. About 75 % of patients 
with acute HCV infection develop chronic 
infection and 20 % of them develop liver 
cirrhosis after 2 decades (29). A study was 
done in Mashhad in which 67% and 33% of 
HCV-infected patients were women and men, 
respectively. Generally, less than one percent 
of people from Mashhad are infected by HCV 
(30). Data from a systematic review showed 
that 0.16 percent of Iranian population are 
infected by HCV (31).  The number of people 
infected with HCV in the world continues to 
rise and it is predicted that about 3 million 
people will be infected by this virus annually. 
Although this virus is endemic in the world, 
yet in some regions the number of patients is 
different. Africa, Southeast Asia, and Latin 
America have the highest genotypes variations 
and North America, European countries, and 
Australia have the lowest genotypes variations 
(32). 
The most important medicines that are used for 
the treatment of this virus are peginterferon 
and Ribavirin. But only 40-50 % of people 
with HCV genotype 1 can be cured (33). In 
2011, new medications with the name of 
direct-acting antivirals (DAA) were developed 
 
Chart.  3.  Sigmoid curve of virus multiplication 
 
 
Chart.  4.  The standard curve by concentration and CT 
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and represented a breakthrough in HCV 
treatment. They have more than 90% response 
to treat most of the genotypes. The duration of 
treatment is between 12 to 24 weeks (34).  
There are new FDA approved medicines for 
HCV treatment such as Telaprevir, 
Paritaprevir, Boceprevir, and Simeprevir which 
inhibit NS3/4A protease. Daclatasvir inhibits 
NS5A and Sofosbuvir inhibits NS5B (2-4). 
The safety of Simeprevir is generally 
acceptable. Some of the most adverse effects 
of peginterferon and Ribavirin are fatigue, 
influenza-like illness, pruritus, headache, and 
nausea. Patients taking simeprevir might cause 
increased frequency and severity of 
hyperbilirubinemia (35). Some adverse effects 
of Sofosbuvir were reported when it was 
combined with peginterferon and/or longer 
treatment occurred including fatigue, 
headache, nausea, insomnia, pruritus, 
irritability, anemia, asthenia, and diarrhea. 
When this medicine was combined with 
Ribavirin and peginterferon, the adverse 
effects on appetite, influenza like illness, 
pyrexia, chills, neutropenia, and myalgia were 
decreased. Daclatasvir is generally tolerated 
well and the most prevalent adverse effects of 
it are headache, fatigue, nausea, and diarrhea 
(34). The other disadvantage of DAA can be 
their expensiveness. For instance, the cost of 
taking Sofosbuvir for 12 weeks is 84000 
dollars (36). 
Ribavirin is a teratogenic medicine for both 
men and women. That is the reason for 
avoiding pregnancy during and 6 months after 
the end of therapy. Also breastfeeding should 
not be done. Developing reversible arrhythmia 
or cardiomyopathy is rare in patients with 
cardiac problems while they are treating with 
interferon. Because death from cardiac failure 
is more likely to happen in patients who are 
suffering from both HCV and significant 
cardiac disease, anti-viral therapy can be 
dispensed. Other reasons that can stop the use 
of Ribavirin and peginterferon are hepatic 
decompensation and renal failure. These 
medicines can enhance liver failure and 
monitoring of patients are needed. Renal 
failure will increase the amount of Ribavirin 
and peginterferon in patients' serum that may 
cause hemolysis. The immune system of 
patients is influenced by these medicines and 
probably this is the mechanism of their 
antiviral activities. In HCV patients with 
comorbid autoimmune diseases, both 
medicines can make the condition worse. For 
this reason, the treatment will be dangerous 
when the autoimmune disease is not controlled. 
The most common adverse effects of 
peginterferon are fatigue, muscle aches and 
psychological disorders such as depression, 
irritability, anxiety and sleep disturbance. The 
most common adverse effects of ribavirin are 
hemolysis and anemia. Some other adverse 
effects that are rare are hearing impairment, 
hair thinning and loss, insomnia, visual 
disorders, interstitial pneumonia, pancreatitis, 
colitis and exacerbation of inflammatory 
diseases (37). 
As herbal medicines are safe, efficient, and 
cost-effective, using them has attracted many 
attentions (5). Studies show there are some 
herbal medicines which have anti HCV effects 
including Milk Thistle, Glycyrrhizin, Kampo, 
Phyllanthus, Cinnamon, and Curcumin. 
Curcumin is used as a treatment of many 
diseases including Inflammatory Bowel 
Disease, Irritable Bowel Syndrome, 
Postoperative Inflammation, Arthritis, 
Psoriasis(38), and some Bactria such as Vibrio 
harveyi, Bacillus subtilis, 
Aeromonashydrophila, Staphylococcus aureus, 
Streptococcus agalactiae and some viruses 
such as HIV, Influenza virus, Herpes simplex 
virus-1 and 2, Coxsackievirus, Hepatitis B 
virus, Hepatitis C virus, and Human Papilloma 
virus, and Japanese encephalitis virus (16-24).  
Nanomicelles are self-assembling nanosized 
colloidal dispersions with sizes between 10 to 
100 nm. They have a hydrophobic core and 
hydrophilic shell. Nanomicelles are used as 
carriers of hydrophobic medicines as many 
medicines are hydrophobic (25). 
So far, there is few studies about herbal 
medicines in nanomicelles because most herbal 
medicines are hydrophilic.  
Curcumin nanomicelles have been developed 
for oral use because they have a high 
bioavailability compared to the ordinary 
version of curcumin. After taking capsules, the 
soft gels of SinaCurcumin opens and 
transitpasses into the small intestine from the 
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stomach after less than 15 minutes. Curcumin 
nanomicelles could be dissolved in unstirred 
water layer after reaching the small intestine. 
Unlike curcumin which is insoluble in water, 
curcumin nanomicelles can be absorbed in GI 
tract because they are soluble in water. As 
curcumin is not water soluble, many methods 
have been suggested to make it water soluble. 
Preparing curcumin as nanomicelles is one of 
the most successful methods (39).    
A study showed curcumin can decrease the 
gene expression of HCV via suppression of the 
Akt-SREBP-1 activation, not by NF-kB 
pathway. Curcumin has anti-cancer effects 
against anti-hepatocellular carcinoma (13). 
A study by Anggakusuma et al in 2014 showed 
curcumin could inhibit the entry of HCV, but 
could not inhibit HCV RNA replication or viral 
assembly/release in Huh7.5 cells (14). 
So far a few studies about anti-viral effects of 
curcumin nanomicelles have been done, 
A study by Mohammadi et al in 2014 showed 
curcumin nanomicelles could have anti-HTLV-
1 effects (14). In our study, this type of 
curcumin could decrease the viral load of 
HCV. 
Conclusion 
 
After treatment of HCV infected cells with 
peginterferon and curcumin nanomicelles, it 
was shown that the viral load of HCV infected 
cells treated with peginterferon were increased, 
but this viral load for cells treated with 
curcumin nanomicelles were decreased. 
It is suggested that curcumin nanomicelles can 
have anti-viral effects on the attachment and 
entry of hepatitis C infection. Further study on 
the mechanism of curcumin nanomicelles 
effect is suggested. 
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